{"analyses":[{"ciLowerLimit":"0.87","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.36","estimateComment":"computed using a cox proportional hazard model stratified by randomization PDL-1 and HPV status","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"1.09"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.52","upperLimit":"11.47","value":"9.76"},{"groupId":"OG001","lowerLimit":"8.48","upperLimit":"14.00","value":"11.30"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"282"},{"groupId":"OG001","value":"143"}],"units":"Participants"}],"description":"Overall survival was defined as the time from randomization to the date of death from any cause. Participants were censored at the date they were last known to be alive and at the date of randomization if they were randomized but had no follow-up.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in both Platinum Refractory Subgroup and Platinum Eligible Subgroup treated with Nivolumab 3 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W","id":"OG000","title":"Treatment A"},{"description":"Participants in both Platinum Refractory Subgroup and Platinum Eligible Subgroup treated with Nivolumab 3 mg/kg Q2W + Ipilimumab-Placebo Q6W","id":"OG001","title":"Treatment B"}],"paramType":"MEDIAN","populationDescription":"All Randomized Participants","reportingStatus":"POSTED","timeFrame":"From randomization to death. Approximately 63 Months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}